Micaela Ebert

Micaela Ebert

Auto-generated profile, based on publicly available information

Micaela Ebert

Heart Center Dresden, Technische Universität Dresden , Dresden

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
KZKatja Zeppenfeld
Katja Zeppenfeld
RRRobert Rademaker
Robert Rademaker
AAAmin Al-Ahmad
Amin Al-Ahmad
CCCorrado Carbucicchio
Corrado Carbucicchio
CCChistian de Chillou
Chistian de Chillou
CTClaudio Tondo
Claudio Tondo
Stereotactic arrhythmia radioablation (STAR) is a novel, non-invasive, and promising treatment option for ventricular arrhythmias (VAs). It has been applied in highly selected patients mainly as bailout procedure, when (multiple) catheter ablations, together with anti-arrhythmic drugs, were unable to control the VAs. Despite the increasing clinical use, there is still limited knowledge of the acute and long-term response of normal and diseased myocardium to STAR. Acute toxicity appeared to be reasonably low, but potential late adverse effects may be underreported. Among published studies, the provided methodological information is often limited, and patient selection, target volume definition, methods for determination and transfer of target volume, and techniques for treatment planning and execution differ across studies, hampering the pooling of data and comparison across studies. In addition, STAR requires close and new collaboration between clinical electrophysiologists and radiation oncologists, which is facilitated by shared knowledge in each collaborator's area of expertise and a common language. This clinical consensus statement provides uniform definition of cardiac target volumes. It aims to provide advice in patient selection for STAR including aetiology-specific aspects and advice in optimal cardiac target volume identification based on available evidence. Safety concerns and the advice for acute and long-term monitoring including the importance of standardized reporting and follow-up are covered by this document. Areas of uncertainty are listed, which require high-quality, reliable pre-clinical and clinical evidence before the expansion of STAR beyond clinical scenarios in which proven therapies are ineffective or unavailable.

6 July 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
MEMicaela Ebert
Micaela Ebert
NJNikolaus Jander
Nikolaus Jander
JMJan Minners
Jan Minners
TBThomas Blum
Thomas Blum
MDMichael Doering
Michael Doering
SRSergio Richter
Sergio Richter
Background: There is limited evidence of long‐term impact of right ventricular pacing on left ventricular ( LV ) systolic function in pacemaker recipients with preserved LV ejection fraction ( LVEF ). The objective of the study was to evaluate the outcome and echocardiographic course of baseline preserved LVEF in a large cohort of pacemaker recipients with respect to pacing indication and degree of right ventricular pacing. Methods and Results: We enrolled 991 patients (73±10 years, 54% male) with baseline normal (>55%) LVEF (n=791) or mildly reduced (41–55%) LVEF (n=200) who had paired echocardiographic data on LV systolic function recorded at implantation and last follow‐up. According to pacing indication, patients were divided into atrioventricular block group A (n=500) and sinus node disease group B (n=491). Main outcome measures were all‐cause mortality and deterioration of LV function ≥2 LVEF categories at last follow‐up. Patients were followed for an average of 44 months. Death from any cause occurred in 166 (17%), and deterioration of LV function ≥2 LVEF categories in 56 (6%) patients. There was no significant difference in outcome between group A and group B either in patients with normal LVEF or in those with mildly reduced LVEF . Mean percentage of right ventricular pacing was not predictive of outcome. Conclusions: In a large cohort of pacemaker recipients with predominantly normal LVEF , clinically relevant LV dysfunction develops rather infrequently. No significant difference in all‐cause mortality and development of severe LV dysfunction is observed between patients with atrioventricular block and sinus node disease. Accordingly, de novo biventricular pacing cannot be recommended for patients with preserved LVEF .

1 April 2019 in Heart Rhythm
Verified
Journal Article
Closed access
MEMicaela Ebert
Micaela Ebert
SRSergio Richter
Sergio Richter
BDBorislav Dinov
Borislav Dinov
KZKatja Zeppenfeld
Katja Zeppenfeld
GHGerhard Hindricks
Gerhard Hindricks

1 July 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
MDMichael Döring
Michael Döring
MEMicaela Ebert
Micaela Ebert
NDNikolaos Dagres
Nikolaos Dagres
Andreas MüssigbrodtAndreas Müssigbrodt
Andreas Müssigbrodt
KBKerstin Bode
Kerstin Bode
SRSergio Richter
Sergio Richter

30 December 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
SRSergio Richter
Sergio Richter
RGRoman Gebauer
Roman Gebauer
MEMicaela Ebert
Micaela Ebert
CLCathleen Moscoso Ludueña
Cathleen Moscoso Ludueña
DSDominik Scheller
Dominik Scheller
MDMichael Döring
Michael Döring
Left bundle branch area pacing (LBBAP) can be technically challenging and fluoroscopy-intense. Three-dimensional electroanatomical mapping (EAM) facilitates non-fluoroscopic lead navigation and electrogram mapping. We sought to prospectively evaluate the feasibility, safety, and outcomes of routine EAM-guided LBBAP in patients with structural heart disease (SHD) and advanced conduction abnormalities. Consecutive patients with SHD and conduction abnormalities who underwent an attempt at EAM-guided LBBAP were included. The feasibility, safety, procedural, and mid-term outcomes were evaluated. Electrical, echocardiographic, and clinical parameters were assessed at implantation and last follow-up. Thirty-two patients (68 ± 18 years; 19% female) were included, of which 75% had intrinsic QRS > 150 ms, 53% left bundle branch block, and 25% right bundle branch block. Primary EAM-guided LBBAP was successful in 29 patients (91%). The procedural duration was 95 (70–110) min, total fluoroscopy time 0.93 (0.40–1.73) min, and total fluoroscopy dose 35.4 (20.5–77.2) cGy cm2. Paced QRS duration (QRSd) was significantly shorter than intrinsic QRSd (121.9 ± 10.7 vs. 159.2 ± 34.4 ms; P < 0.001) and remained stable during the mean follow-up of 7.0 ± 5.9 months. The LBBAP capture threshold was 0.57 ± 0.23 V/0.4 ms at implantation and remained low during follow-up (0.58 ± 0.18 V/0.5 ± 0.2 ms; P = 0.877). Overall left ventricular ejection fraction improved significantly from 44.2 ± 14.3% at baseline to 49.4 ± 13.1% at follow-up (P = 0.009), New York Heart Association class from 2.4 ± 0.6 to 1.8 ± 0.6 (P = 0.002), respectively. No complications occurred that required intervention. Routine near-zero fluoroscopy EAM-guided LBBAP can safely be performed in patients with SHD and advanced conduction abnormalities with high success rates and favourable mid-term outcomes. Further studies are needed to investigate whether the use of EAM improves the overall outcome of conduction system pacing and to identify specific patient populations who benefit the most from EAM-guided lead implantation.

20 December 2023 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
KZKatja Zeppenfeld
Katja Zeppenfeld
YKYoshitaka Kimura
Yoshitaka Kimura
MEMicaela Ebert
Micaela Ebert